Clinical trials testing the efficacy of CD20 monoclonal antibody in treating systemic sclerosis-associated PAH are ongoing, suggesting that CD20-marked B cells play a role in pulmonary vascular remodeling.[25] This study found a positive correlation between CD20-CD38-AC and PAH. This evidence concerns the gene CD38 and systemic sclerosis.